124 related articles for article (PubMed ID: 8520756)
1. Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ.
Seersholm N; Kok-Jensen A; Dirksen A
Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):1922-5. PubMed ID: 8520756
[TBL] [Abstract][Full Text] [Related]
2. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.
Am J Respir Crit Care Med; 1998 Jul; 158(1):49-59. PubMed ID: 9655706
[TBL] [Abstract][Full Text] [Related]
3. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ).
Piitulainen E; Eriksson S
Eur Respir J; 1999 Feb; 13(2):247-51. PubMed ID: 10065663
[TBL] [Abstract][Full Text] [Related]
4. [Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Pneumologie; 1998 Oct; 52(10):545-52. PubMed ID: 9847632
[TBL] [Abstract][Full Text] [Related]
5. Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha 1-antitrypsin deficiency.
Seersholm N; Kok-Jensen A
Am J Respir Crit Care Med; 1995 Feb; 151(2 Pt 1):369-73. PubMed ID: 7842193
[TBL] [Abstract][Full Text] [Related]
6. Aspects of treatment in alpha 1-antitrypsin deficiency: insights derived from a Swedish PiZZ series.
Eriksson S; Wu MC
Eur Respir J Suppl; 1990 Mar; 9():39s-43s. PubMed ID: 2340050
[TBL] [Abstract][Full Text] [Related]
7. Decline in pulmonary function in patients with alpha 1-antitrypsin deficiency.
Evald T; Dirksen A; Keittelmann S; Viskum K; Kok-Jensen A
Lung; 1990; 168 Suppl():579-85. PubMed ID: 2117166
[TBL] [Abstract][Full Text] [Related]
8. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis.
Silverman EK; Chapman HA; Drazen JM; Weiss ST; Rosner B; Campbell EJ; O'DONNELL WJ; Reilly JJ; Ginns L; Mentzer S; Wain J; Speizer FE
Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1770-8. PubMed ID: 9620904
[TBL] [Abstract][Full Text] [Related]
9. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
10. Deficient alpha-1-antitrypsin phenotypes and persistent airflow limitation in severe asthma.
van Veen IH; ten Brinke A; van der Linden AC; Rabe KF; Bel EH
Respir Med; 2006 Sep; 100(9):1534-9. PubMed ID: 16476537
[TBL] [Abstract][Full Text] [Related]
11. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N
Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency.
Seersholm N; Kok-Jensen A
Thorax; 1998 Apr; 53(4):265-8. PubMed ID: 9741368
[TBL] [Abstract][Full Text] [Related]
13. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences.
Xu X; Weiss ST; Rijcken B; Schouten JP
Eur Respir J; 1994 Jun; 7(6):1056-61. PubMed ID: 7925873
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group.
Turino GM; Barker AF; Brantly ML; Cohen AB; Connelly RP; Crystal RG; Eden E; Schluchter MD; Stoller JK
Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1718-25. PubMed ID: 8970361
[TBL] [Abstract][Full Text] [Related]
15. Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, PiZZ.
Wu MC; Eriksson S
J Clin Epidemiol; 1988; 41(12):1157-65. PubMed ID: 3264848
[TBL] [Abstract][Full Text] [Related]
16. Heritability of lung function in severe alpha-1 antitrypsin deficiency.
DeMeo DL; Campbell EJ; Brantly ML; Barker AF; Eden E; McElvaney NG; Rennard SI; Stocks JM; Stoller JK; Strange C; Turino G; Sandhaus RA; Silverman EK
Hum Hered; 2009; 67(1):38-45. PubMed ID: 18931508
[TBL] [Abstract][Full Text] [Related]
17. [The variability of clinical presentation of chronic obstructive pulmonary disease in patients with hereditary alpha-1 antitrypsin deficiency].
Kuca P; Kamiński D; Campbell E; Kołakowski J; Goljan-Geremek A; Puścińska E; Bieleń P; Nowiński A; Wojda E; Hawryłkiewicz I; Sliwiński P; Górecka D
Pneumonol Alergol Pol; 2004; 72(9-10):420-3. PubMed ID: 16021998
[TBL] [Abstract][Full Text] [Related]
18. Decline in FEV1 in patients with PiZ alpha-1-antitrypsin deficiency: the Australian experience.
Burdon JG; Brenton S; Hocking V; Knight KR; Ayad M; Cook L; Janus ED
Respirology; 2002 Mar; 7(1):51-5. PubMed ID: 11896901
[TBL] [Abstract][Full Text] [Related]
19. Smoking, lung function, and alpha 1-antitrypsin deficiency.
Janus ED; Phillips NT; Carrell RW
Lancet; 1985 Jan; 1(8421):152-4. PubMed ID: 2857224
[TBL] [Abstract][Full Text] [Related]
20. Effects of smoking and intermediate alpha 1-antitrypsin deficiency (PiMZ) on lung function.
Eriksson S; Lindell SE; Wiberg R
Eur J Respir Dis; 1985 Oct; 67(4):279-85. PubMed ID: 3878302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
